Symbol="AKTX"
AssetType="Common Stock"
Name="Akari Therapeutics PLC"
Description="Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom."
CIK="1541157"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="24 WEST 40TH STREET, 8TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2022-06-30"
MarketCapitalization="25279000"
EBITDA="-23084500"
PERatio="None"
PEGRatio="0"
BookValue="0.024"
DividendPerShare="0"
DividendYield="0"
EPS="-0.3"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-1.133"
ReturnOnEquityTTM="-4.832"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.3"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="2.75"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="3.432"
EVToRevenue="-"
EVToEBITDA="-1.11"
Beta="1.345"
num_52WeekHigh="1.61"
num_52WeekLow="0.14"
num_50DayMovingAverage="0.182"
num_200DayMovingAverage="0.333"
SharesOutstanding="101116000"
DividendDate="None"
ExDividendDate="None"
symbol="AKTX"
open="0.27"
high="0.27"
low="0.25"
price="0.25"
volume="348940.00"
latest_trading_day="2023-08-08"
previous_close="0.27"
change="-0.01"
change_percent="-5.5807%"
aroon_positive_momentum_days="7"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="7"
Volume_recent_avg="578987"
Change_recent_avg="0.01"
Delta_recent_avg="0.02"
Variance_recent_avg="0.01"
Change_ratio_recent_avg="-1.58"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="7"
Aroon_momentum_negative="93"
image_negative_thumbnail_id_1="1163"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0197.jpeg"
image_negative_thumbnail_id_2="1133"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0166.jpeg"
image_neutral_thumbnail_id_1="560"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_neutral_thumbnail_id_2="591"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0008.jpeg"
image_positive_thumbnail_id_1="621"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0087.jpeg"
image_positive_thumbnail_id_2="1016"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0178.jpeg"
image_professor_thumbnail_id_1="1171"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
image_professor_thumbnail_id_2="1187"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
